These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

457 related articles for article (PubMed ID: 25597486)

  • 1. Loss of MyD88 leads to more aggressive TRAMP prostate cancer and influences tumor infiltrating lymphocytes.
    Peek EM; Song W; Zhang H; Huang J; Chin AI
    Prostate; 2015 Apr; 75(5):463-73. PubMed ID: 25597486
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Increased expression of MUC18 correlates with the metastatic progression of mouse prostate adenocarcinoma in the TRAMP model.
    Wu GJ; Fu P; Chiang CF; Huss WJ; Greenberg NM; Wu MW
    J Urol; 2005 May; 173(5):1778-83. PubMed ID: 15821586
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic ablation of the amplified-in-breast cancer 1 inhibits spontaneous prostate cancer progression in mice.
    Chung AC; Zhou S; Liao L; Tien JC; Greenberg NM; Xu J
    Cancer Res; 2007 Jun; 67(12):5965-75. PubMed ID: 17575167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Constitutive activation of P I3 K-Akt and NF-kappaB during prostate cancer progression in autochthonous transgenic mouse model.
    Shukla S; Maclennan GT; Marengo SR; Resnick MI; Gupta S
    Prostate; 2005 Aug; 64(3):224-39. PubMed ID: 15712212
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Broadening of transgenic adenocarcinoma of the mouse prostate (TRAMP) model to represent late stage androgen depletion independent cancer.
    Jeet V; Ow K; Doherty E; Curley B; Russell PJ; Khatri A
    Prostate; 2008 Apr; 68(5):548-62. PubMed ID: 18247402
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic deletion of osteopontin in TRAMP mice skews prostate carcinogenesis from adenocarcinoma to aggressive human-like neuroendocrine cancers.
    Mauri G; Jachetti E; Comuzzi B; Dugo M; Arioli I; Miotti S; Sangaletti S; Di Carlo E; Tripodo C; Colombo MP
    Oncotarget; 2016 Jan; 7(4):3905-20. PubMed ID: 26700622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive bioluminescent detection of prostate cancer growth and metastasis in a bigenic transgenic mouse model.
    Hsieh CL; Xie Z; Yu J; Martin WD; Datta MW; Wu GJ; Chung LW
    Prostate; 2007 May; 67(7):685-91. PubMed ID: 17342752
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Characterization of prostatic epithelial cell lines derived from transgenic adenocarcinoma of the mouse prostate (TRAMP) model.
    Foster BA; Gingrich JR; Kwon ED; Madias C; Greenberg NM
    Cancer Res; 1997 Aug; 57(16):3325-30. PubMed ID: 9269988
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disruption of arginase II alters prostate tumor formation in TRAMP mice.
    Mumenthaler SM; Rozengurt N; Livesay JC; Sabaghian A; Cederbaum SD; Grody WW
    Prostate; 2008 Oct; 68(14):1561-9. PubMed ID: 18663728
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Toll-like receptor 3-mediated suppression of TRAMP prostate cancer shows the critical role of type I interferons in tumor immune surveillance.
    Chin AI; Miyahira AK; Covarrubias A; Teague J; Guo B; Dempsey PW; Cheng G
    Cancer Res; 2010 Apr; 70(7):2595-603. PubMed ID: 20233880
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Activation of Nod1 and Nod2 induces innate immune responses of prostate epithelial cells.
    Kang MJ; Heo SK; Song EJ; Kim DJ; Han SY; Han JH; Kim BY; Park JH
    Prostate; 2012 Sep; 72(12):1351-8. PubMed ID: 22228081
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genistein alters growth factor signaling in transgenic prostate model (TRAMP).
    Wang J; Eltoum IE; Lamartiniere CA
    Mol Cell Endocrinol; 2004 Apr; 219(1-2):171-80. PubMed ID: 15149738
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dysfunctional transforming growth factor-beta receptor II accelerates prostate tumorigenesis in the TRAMP mouse model.
    Pu H; Collazo J; Jones E; Gayheart D; Sakamoto S; Vogt A; Mitchell B; Kyprianou N
    Cancer Res; 2009 Sep; 69(18):7366-74. PubMed ID: 19738062
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A null-mutation in the Znt7 gene accelerates prostate tumor formation in a transgenic adenocarcinoma mouse prostate model.
    Tepaamorndech S; Huang L; Kirschke CP
    Cancer Lett; 2011 Sep; 308(1):33-42. PubMed ID: 21621325
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The insulin-like growth factor axis and prostate cancer: lessons from the transgenic adenocarcinoma of mouse prostate (TRAMP) model.
    Kaplan PJ; Mohan S; Cohen P; Foster BA; Greenberg NM
    Cancer Res; 1999 May; 59(9):2203-9. PubMed ID: 10232609
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characterization of the autochthonous transgenic adenocarcinoma of the mouse prostate (TRAMP) as a model to study effects of castration therapy.
    Wikström P; Lindahl C; Bergh A
    Prostate; 2005 Feb; 62(2):148-64. PubMed ID: 15389804
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Androgen-independent prostate cancer progression in the TRAMP model.
    Gingrich JR; Barrios RJ; Kattan MW; Nahm HS; Finegold MJ; Greenberg NM
    Cancer Res; 1997 Nov; 57(21):4687-91. PubMed ID: 9354422
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Gene expression profile of mouse prostate tumors reveals dysregulations in major biological processes and identifies potential murine targets for preclinical development of human prostate cancer therapy.
    Haram KM; Peltier HJ; Lu B; Bhasin M; Otu HH; Choy B; Regan M; Libermann TA; Latham GJ; Sanda MG; Arredouani MS
    Prostate; 2008 Oct; 68(14):1517-30. PubMed ID: 18668517
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Regression of mouse prostatic intraepithelial neoplasia by nonsteroidal anti-inflammatory drugs in the transgenic adenocarcinoma mouse prostate model.
    Narayanan BA; Narayanan NK; Pittman B; Reddy BS
    Clin Cancer Res; 2004 Nov; 10(22):7727-37. PubMed ID: 15570007
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased fatty acid synthase expression and activity during progression of prostate cancer in the TRAMP model.
    Pflug BR; Pecher SM; Brink AW; Nelson JB; Foster BA
    Prostate; 2003 Nov; 57(3):245-54. PubMed ID: 14518031
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.